Question

A 50-year-old patient with heart failure with reduced ejection fraction (HFrEF) is stable on an ACE inhibitor and a beta-blocker. He remains symptomatic despite optimal doses. Which drug class should be considered next to reduce mortality?

Accepted Answer

C. Mineralocorticoid receptor antagonist (e.g., spironolactone)

Answer

A. Loop diuretic

Answer

B. Ivabradine

Answer

D. Digoxin

Answer

E. Angiotensin Receptor Blocker (ARB) in addition to ACE inhibitor

Practice question

A 50-year-old patient with heart failure with reduced ejection fraction (HFrEF) is stable on an ACE inhibitor and a beta-blocker. He remains symptomatic despite optimal doses. Which drug class should be considered next to reduce mortality?